The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies
Crossref DOI link: https://doi.org/10.1186/s12931-016-0372-1
Published Online: 2016-05-23
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jones, Paul W.
Leidy, Nancy K.
Hareendran, Asha
Lamarca, Rosa
Chuecos, Ferran
Garcia Gil, Esther
Funding for this research was provided by:
Almirall S.A., Barcelona, Spain
AstraZeneca